Analyst: This is Novo’s challenge on the obesity market
According to pharmaceutical analyst, Søren Løntoft Hansen, it is not the pending cancer case which is the biggest challenge for the entry of Novo’s diabetes drug Victoza on the obesity market. Meanwhile, he raises his peak sales estimate for the drug considerably.
by Stefan Singh Kailay
At a hearing in the U.S. last week, Novo Nordisk presented their side of the matter in a pending case about the potential effect of GLP-1 analogues on the development of pancreatitis and pancreatic cancer. One of the drugs being targeted in the case is the company’s blockbuster Victoza.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
